1. Home
  2. URGN vs TRNS Comparison

URGN vs TRNS Comparison

Compare URGN & TRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • URGN
  • TRNS
  • Stock Information
  • Founded
  • URGN 2004
  • TRNS 1964
  • Country
  • URGN United States
  • TRNS United States
  • Employees
  • URGN N/A
  • TRNS N/A
  • Industry
  • URGN Biotechnology: Pharmaceutical Preparations
  • TRNS Electrical Products
  • Sector
  • URGN Health Care
  • TRNS Industrials
  • Exchange
  • URGN Nasdaq
  • TRNS Nasdaq
  • Market Cap
  • URGN 831.6M
  • TRNS 748.7M
  • IPO Year
  • URGN 2017
  • TRNS N/A
  • Fundamental
  • Price
  • URGN $19.22
  • TRNS $77.41
  • Analyst Decision
  • URGN Strong Buy
  • TRNS Buy
  • Analyst Count
  • URGN 8
  • TRNS 4
  • Target Price
  • URGN $29.00
  • TRNS $108.67
  • AVG Volume (30 Days)
  • URGN 1.3M
  • TRNS 76.0K
  • Earning Date
  • URGN 08-07-2025
  • TRNS 08-06-2025
  • Dividend Yield
  • URGN N/A
  • TRNS N/A
  • EPS Growth
  • URGN N/A
  • TRNS N/A
  • EPS
  • URGN N/A
  • TRNS 1.57
  • Revenue
  • URGN $91,871,000.00
  • TRNS $278,421,000.00
  • Revenue This Year
  • URGN $39.80
  • TRNS $10.85
  • Revenue Next Year
  • URGN $108.94
  • TRNS $6.52
  • P/E Ratio
  • URGN N/A
  • TRNS $49.69
  • Revenue Growth
  • URGN 8.98
  • TRNS 7.30
  • 52 Week Low
  • URGN $3.42
  • TRNS $67.56
  • 52 Week High
  • URGN $19.69
  • TRNS $141.27
  • Technical
  • Relative Strength Index (RSI)
  • URGN 76.29
  • TRNS 36.19
  • Support Level
  • URGN $18.37
  • TRNS $80.40
  • Resistance Level
  • URGN $19.36
  • TRNS $84.99
  • Average True Range (ATR)
  • URGN 1.03
  • TRNS 2.82
  • MACD
  • URGN 0.25
  • TRNS -0.65
  • Stochastic Oscillator
  • URGN 91.26
  • TRNS 8.25

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About TRNS Transcat Inc.

Transcat Inc is involved in providing calibration and laboratory instrument services and distribution of test, measurement, and control instrumentation. Its product and services portfolio consists of calibration instruments, dimensional measuring tools, Electrical test instruments, pressure measurement, etc. The firm has Service and Distribution operating segments. It derives the majority of its revenues from the Service segment. The firm promotes and sells its products under brand names such as Estech, FLIR, Fluke, Keysight, and Megger among others. It serves to pharmaceutical, industrial manufacturing, energy, and chemical process industries.

Share on Social Networks: